FGGY

Summary

FGGY (FGGY carbohydrate kinase domain containing, HGNC:25610) is a protein-coding gene on chromosome 1p32.1, encoding FGGY carbohydrate kinase domain-containing protein (Q96C11). Catalyzes ATP-dependent phosphorylation of D-ribulose at C-5 to form D-ribulose 5-phosphate.

This gene encodes a protein that phosphorylates carbohydrates such as ribulose, ribitol, and L-arabinitol. Genome-wide association studies in some populations have found an association between polymorphisms in this gene and sporadic amyotrophic lateral sclerosis, but studies of other populations have not been able to replicate this association. Alternative splicing results in multiple transcript variants.

Source: NCBI Gene 55277 — RefSeq curated summary.

At a glance

• GWAS associations: 18
• Clinical variants (ClinVar): 120 total
• MANE Select transcript: NM_018291

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:25610
Approved symbol	FGGY
Name	FGGY carbohydrate kinase domain containing
Location	1p32.1
Locus type	gene with protein product
Status	Approved
Aliases	FLJ10986
Ensembl gene	ENSG00000172456
Ensembl biotype	protein_coding
OMIM	611370
Entrez	55277

Gene structure

Transcript identifiers

Ensembl transcripts: 60 — 41 protein_coding, 11 protein_coding_CDS_not_defined, 7 nonsense_mediated_decay, 1 retained_intron

ENST00000303721, ENST00000371210, ENST00000371212, ENST00000371218, ENST00000413489, ENST00000424725, ENST00000430447, ENST00000462744, ENST00000466791, ENST00000471169, ENST00000472783, ENST00000474476, ENST00000475949, ENST00000476939, ENST00000480847, ENST00000485720, ENST00000493891, ENST00000495718, ENST00000582567, ENST00000583635, ENST00000634364, ENST00000634399, ENST00000634606, ENST00000635156, ENST00000635297, ENST00000894270, ENST00000894271, ENST00000894272, ENST00000894273, ENST00000894274, ENST00000894275, ENST00000894276, ENST00000894277, ENST00000894278, ENST00000894279, ENST00000894280, ENST00000894281, ENST00000894282, ENST00000894283, ENST00000894284, ENST00000894285, ENST00000894286, ENST00000894287, ENST00000894288, ENST00000894289, ENST00000894290, ENST00000894291, ENST00000894292, ENST00000894293, ENST00000894294, ENST00000939057, ENST00000939058, ENST00000941446, ENST00000941447, ENST00000941448, ENST00000941449, ENST00000941450, ENST00000941451, ENST00000941452, ENST00000941453

RefSeq mRNA: 14 — MANE Select: NM_018291 NM_001113411, NM_001244714, NM_001278224, NM_001350790, NM_001350791, NM_001350792, NM_001350793, NM_001350794, NM_001350795, NM_001350796, NM_001350797, NM_001350798, NM_001350799, NM_018291

CCDS: CCDS44155, CCDS58003, CCDS60155, CCDS611

Canonical transcript exons

ENST00000303721 — 16 exons

Exon	Start	End
ENSE00003469176	59378749	59378837
ENSE00003473209	59667283	59667403
ENSE00003490352	59554124	59554227
ENSE00003496354	59660219	59660293
ENSE00003547913	59346247	59346398
ENSE00003559410	59512311	59512439
ENSE00003592558	59339958	59340069
ENSE00003603847	59625988	59626049
ENSE00003609460	59321536	59321750
ENSE00003616318	59674039	59674133
ENSE00003625837	59757931	59757992
ENSE00003627347	59607803	59607910
ENSE00003648044	59456961	59457076
ENSE00003653980	59762503	59762730
ENSE00003687418	59638228	59638375
ENSE00003902984	59297094	59297150

Expression profiles

Bgee: expression breadth ubiquitous, 213 present calls, max score 96.18.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 6.6521 / max 87.1634, expressed in 1746 samples.

FANTOM5 promoters (11 alternative TSS)

Promoter ID	TPM avg	Samples expressed
3043	4.4305	1565
3041	1.1039	573
3042	0.5612	310
3052	0.3446	94
3049	0.0478	19
3051	0.0337	16
3044	0.0309	13
3050	0.0297	10
3046	0.0295	5
201527	0.0238	6

Top tissues by expression

278 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right lobe of liver	UBERON:0001114	96.18	gold quality
hindlimb stylopod muscle	UBERON:0004252	92.29	gold quality
gastrocnemius	UBERON:0001388	92.12	gold quality
muscle of leg	UBERON:0001383	91.98	gold quality
liver	UBERON:0002107	91.87	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	91.12	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	89.58	gold quality
calcaneal tendon	UBERON:0003701	89.05	gold quality
muscle organ	UBERON:0001630	88.81	gold quality
right adrenal gland	UBERON:0001233	88.64	gold quality
right adrenal gland cortex	UBERON:0035827	88.55	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	88.35	gold quality
colonic epithelium	UBERON:0000397	88.08	gold quality
minor salivary gland	UBERON:0001830	88.05	gold quality
corpus epididymis	UBERON:0004359	87.92	gold quality
gluteal muscle	UBERON:0002000	87.77	gold quality
left adrenal gland cortex	UBERON:0035825	87.07	gold quality
left adrenal gland	UBERON:0001234	87.03	gold quality
sural nerve	UBERON:0015488	86.78	gold quality
body of pancreas	UBERON:0001150	86.70	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	86.42	gold quality
right uterine tube	UBERON:0001302	86.15	gold quality
ventricular zone	UBERON:0003053	86.04	gold quality
adenohypophysis	UBERON:0002196	85.96	gold quality
adrenal gland	UBERON:0002369	85.53	gold quality
adrenal cortex	UBERON:0001235	85.22	gold quality
saliva-secreting gland	UBERON:0001044	84.96	gold quality
mouth mucosa	UBERON:0003729	84.80	gold quality
pituitary gland	UBERON:0000007	84.51	gold quality
adrenal tissue	UBERON:0018303	84.28	gold quality

Single-cell (SCXA)

Detected in 5 experiment(s), a significant marker in 5.

Experiment	Marker?	Max mean expression
E-HCAD-1	yes	87.04
E-CURD-119	yes	60.89
E-MTAB-10553	yes	24.89
E-ANND-3	yes	23.81
E-HCAD-9	yes	11.55

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

6 targeting FGGY, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-8068	99.98	73.85	2376
HSA-MIR-1272	99.34	68.79	878
HSA-MIR-5589-3P	99.29	68.30	1443
HSA-MIR-4777-3P	99.15	68.92	626
HSA-MIR-875-5P	96.74	66.48	579
HSA-MIR-193A-5P	95.70	65.33	613

Literature-anchored findings (GeneRIF, showing 7)

• Variants of FLJ10986 may confer susceptibility to sporadic ALS (amyotrophic lateral sclerosis). (PMID:17671248)
• The result of this study suggested that FLJI0986 that do not modulate the risk for SALS in the German population. (PMID:19464757)
• Results suggest that common genetic variation in FGGY is not associated with susceptibility to sporadic ALS in genetically homogeneous populations from northern Europe. (PMID:19922138)
• This study indicated that mutations in fggy genes are unlikely to be a common cause of ALS in the French and French Canadian populations. (PMID:20001489)
• Single-nucleotide polymorphism in FGGY is not associated with amyotrophic lateral sclerosis in a large Chinese cohort. (PMID:24439956)
• S. cerevisiae Ydr109c and human FGGY could act as metabolite repair enzymes, serving to re-phosphorylate free d-ribulose generated by promiscuous phosphatases from d-ribulose 5-phosphate. In human cells, FGGY can additionally participate in ribitol metabolism. (PMID:27909055)
• LINE-1-FGGY expression corresponded with smoke-induced LINE-1 promoter hypomethylation, lipid metabolism dysregulation, and immune microenvironment alteration in the lung squamous cell carcinoma. (PMID:31289132)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	fggy	ENSDARG00000038667
mus_musculus	Fggy	ENSMUSG00000028573
rattus_norvegicus	Fggy	ENSRNOG00000008907
drosophila_melanogaster	CG11594	FBGN0035484

Paralogs (6): XYLB (ENSG00000093217), GK5 (ENSG00000175066), GK2 (ENSG00000196475), SHPK (ENSG00000197417), GK (ENSG00000198814), GK3 (ENSG00000229894)

Protein

Protein identifiers

FGGY carbohydrate kinase domain-containing protein — Q96C11 (reviewed: Q96C11)

Alternative names: D-ribulokinase FGGY

All UniProt accessions (9): A0A0U1RQJ1, A0A0U1RQS3, A0A0U1RR53, A0A0U1RRB9, A0A0U1RRI8, C9J015, Q96C11, F2Z2V1, J3QKV9

UniProt curated annotations — full annotation on UniProt →

Function. Catalyzes ATP-dependent phosphorylation of D-ribulose at C-5 to form D-ribulose 5-phosphate. Postulated to function in a metabolite repair mechanism by preventing toxic accumulation of free D-ribulose formed by non-specific phosphatase activities. Alternatively, may play a role in regulating D-ribulose 5-phosphate recycling in the pentose phosphate pathway. Can phosphorylate ribitol with low efficiency.

Tissue specificity. Expressed in kidney, lung and small intestine and to a lower extent in liver and detected in cerebrospinal fluid (at protein level).

Disease relevance. Amyotrophic lateral sclerosis (ALS) [MIM:105400] A neurodegenerative disorder affecting upper motor neurons in the brain and lower motor neurons in the brain stem and spinal cord, resulting in fatal paralysis. Sensory abnormalities are absent. The pathologic hallmarks of the disease include pallor of the corticospinal tract due to loss of motor neurons, presence of ubiquitin-positive inclusions within surviving motor neurons, and deposition of pathologic aggregates. The etiology of amyotrophic lateral sclerosis is likely to be multifactorial, involving both genetic and environmental factors. The disease is inherited in 5-10% of the cases. Disease susceptibility is associated with variants affecting the gene represented in this entry.

Pathway. Carbohydrate metabolism; pentose and glucuronate interconversion.

Similarity. Belongs to the FGGY kinase family.

Isoforms (6)

UniProt ID	Names	Canonical?
Q96C11-1	1	yes
Q96C11-2	2
Q96C11-4	3
Q96C11-3	4
Q96C11-5	5
Q96C11-6	6

RefSeq proteins (14): NP_001106882, NP_001231643, NP_001265153, NP_001337719, NP_001337720, NP_001337721, NP_001337722, NP_001337723, NP_001337724, NP_001337725, NP_001337726, NP_001337727, NP_001337728, NP_060761* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000577	Carb_kinase_FGGY	Family
IPR006003	FGGY_RbtK-like	Family
IPR018484	FGGY_N	Domain
IPR018485	FGGY_C	Domain
IPR043129	ATPase_NBD	Homologous_superfamily

Pfam: PF00370, PF02782

Enzyme classification (BRENDA):

• EC 2.7.1.47 — D-ribulokinase (BRENDA: 3 organisms, 10 substrates, 3 inhibitors, 10 Km, 0 kcat entries)

Substrate kinetics (BRENDA)

4 substrates with measured Km, best-characterized 4. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
D-RIBULOSE	0.097–0.92	4
RIBITOL	1.468–220	2
ATP	0.83	1
D-ARABITOL	140	1

Catalyzed reactions (Rhea), 1 shown:

• D-ribulose + ATP = D-ribulose 5-phosphate + ADP + H(+) (RHEA:17601)

UniProt features (9 total): splice variant 5, sequence variant 3, chain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96C11-F1	96.13	0.96

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 127 (showing top): ACEVEDO_NORMAL_TISSUE_ADJACENT_TO_LIVER_TUMOR_DN, GOBP_CARBOHYDRATE_PHOSPHORYLATION, TCF4_Q5, DAVICIONI_RHABDOMYOSARCOMA_PAX_FOXO1_FUSION_UP, GOBP_CARBOHYDRATE_METABOLIC_PROCESS, DOUGLAS_BMI1_TARGETS_DN, GOBP_MONOSACCHARIDE_METABOLIC_PROCESS, GRYDER_PAX3FOXO1_ENHANCERS_IN_TADS, GOBP_PENTOSE_METABOLIC_PROCESS, GRYDER_PAX3FOXO1_TOP_ENHANCERS, GOBP_HOMEOSTATIC_PROCESS, GOMF_KINASE_ACTIVITY, GOMF_CARBOHYDRATE_KINASE_ACTIVITY, YOSHIMURA_MAPK8_TARGETS_UP, DODD_NASOPHARYNGEAL_CARCINOMA_DN

GO Biological Process (4): pentose metabolic process (GO:0019321), carbohydrate phosphorylation (GO:0046835), neuron cellular homeostasis (GO:0070050), carbohydrate metabolic process (GO:0005975)

GO Molecular Function (4): D-ribulokinase activity (GO:0019150), kinase activity (GO:0016301), transferase activity (GO:0016740), phosphotransferase activity, alcohol group as acceptor (GO:0016773)

GO Cellular Component (1): cytoplasm (GO:0005737)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
transferase activity, transferring phosphorus-containing groups	2
monosaccharide metabolic process	1
carbohydrate metabolic process	1
phosphorylation	1
cellular homeostasis	1
primary metabolic process	1
phosphotransferase activity, alcohol group as acceptor	1
carbohydrate kinase activity	1
catalytic activity	1
intracellular anatomical structure	1
cellular anatomical structure	1

Protein interactions and networks

STRING

2107 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
FGGY	SHPK	Q9UHJ6	878
FGGY	CTNS	O60931	711
FGGY	ELP3	Q9H9T3	693
FGGY	DPP6	P42658	629
FGGY	DCTN1	Q14203	624
FGGY	KIFAP3	Q92845	571
FGGY	ITPR2	Q14571	571
FGGY	UNC13A	Q9UPW8	571
FGGY	ATXN2	Q99700	506
FGGY	TM2D1	Q9BX74	493
FGGY	VAPB	O95292	491
FGGY	CHRNB4	P30926	490
FGGY	CHRNA4	P43681	490
FGGY	RBM33	Q96EV2	489
FGGY	SMN1	Q16637	477

IntAct

4 interactions, top by confidence:

A	B	Type	Score
NSFL1C	VCP	psi-mi:“MI:0914”(association)	0.970
FGGY	MRPS22	psi-mi:“MI:0915”(physical association)	0.400
FGGY	EAF1	psi-mi:“MI:0915”(physical association)	0.400

BioGRID (10): EAF1 (Affinity Capture-MS), FGGY (Affinity Capture-MS), FGGY (Affinity Capture-MS), EAF1 (Affinity Capture-MS), FGGY (Affinity Capture-RNA), FGGY (Proximity Label-MS), EAF1 (Affinity Capture-MS), FGGY (Affinity Capture-MS), FGGY (Cross-Linking-MS (XL-MS)), FGGY (Affinity Capture-RNA)

ESM2 similar proteins: A2AJL3, A4IPA2, A6QM00, B2VEQ9, B7GGV9, O75191, P0CQ14, P0CQ15, P30646, P37677, P44399, P94524, Q0CH39, Q0P4K0, Q0TVK3, Q2GXN6, Q32LQ3, Q3MIF4, Q3SYZ6, Q3TNA1, Q49V87, Q4V7F3, Q58H57, Q5E9S4, Q5KYP6, Q5R5P3, Q5R830, Q5WL06, Q65GC1, Q6DCD1, Q6FLI1, Q6JQN1, Q6NUW9, Q6PEB4, Q758R9, Q87FK5, Q8BH55, Q8BWU8, Q8IYQ7, Q8K370

Diamond homologs: A1TGD7, A2AJL3, Q04585, Q4R4D5, Q65GC1, Q6DCD1, Q6NUW9, Q826J2, Q96C11, Q9LBQ3, Q9NJP9, Q9RJM2, P11553, P44399, Q8A1A3, Q8X6R3, Q8Z428, Q8ZMC5, P95907, A1A7B0, A4IPA2, A4W6G7, A5ISI2, A6QEK4, A6QGJ8, A6T4K1, A6U1B8, A7WYY2, A7X1U3, A7ZHF4, A7ZW13, A8ALN9, A8FQ89, A8GE05, A8Z1X0, A9MQF0, A9MYN9, B1IRB5, B1KKY8, B1LFZ7

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

120 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	91
Likely benign	5
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

6044 predictions. Top by Δscore:

Variant	Effect	Δscore
1:59321747:AAAGG:A	donor_loss	1.0000
1:59321748:AAGGT:A	donor_loss	1.0000
1:59321750:GGTA:G	donor_loss	1.0000
1:59321751:GTAT:G	donor_loss	1.0000
1:59321752:T:A	donor_loss	1.0000
1:59339951:A:AG	acceptor_gain	1.0000
1:59339952:A:G	acceptor_gain	1.0000
1:59339957:GAAA:G	acceptor_gain	1.0000
1:59340065:GGAAG:G	donor_gain	1.0000
1:59340066:GAAGG:G	donor_gain	1.0000
1:59351297:C:G	donor_gain	1.0000
1:59512299:A:AG	acceptor_gain	1.0000
1:59512299:AT:A	acceptor_gain	1.0000
1:59512300:T:G	acceptor_gain	1.0000
1:59512300:T:TA	acceptor_gain	1.0000
1:59512305:A:AG	acceptor_gain	1.0000
1:59512306:C:G	acceptor_gain	1.0000
1:59512306:CCCA:C	acceptor_loss	1.0000
1:59512307:CCAG:C	acceptor_loss	1.0000
1:59512308:CAGG:C	acceptor_loss	1.0000
1:59512309:A:AG	acceptor_gain	1.0000
1:59512309:AG:A	acceptor_gain	1.0000
1:59512310:G:GC	acceptor_gain	1.0000
1:59512310:GG:G	acceptor_gain	1.0000
1:59512434:GAC:G	donor_gain	1.0000
1:59515433:GAAA:G	donor_gain	1.0000
1:59515436:A:AG	donor_gain	1.0000
1:59515436:A:G	donor_gain	1.0000
1:59625982:TTTCA:T	acceptor_loss	1.0000
1:59625983:TTCA:T	acceptor_loss	1.0000

AlphaMissense

3613 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:59346273:T:A	W114R	0.998
1:59346273:T:C	W114R	0.998
1:59512419:A:T	D260V	0.998
1:59456970:C:G	C188W	0.997
1:59512419:A:C	D260A	0.997
1:59512420:T:A	D260E	0.997
1:59512420:T:G	D260E	0.997
1:59340009:G:C	A85P	0.996
1:59456986:T:A	W194R	0.996
1:59456986:T:C	W194R	0.996
1:59512419:A:G	D260G	0.996
1:59607836:T:A	W313R	0.996
1:59607836:T:C	W313R	0.996
1:59607839:G:A	G314R	0.996
1:59607839:G:C	G314R	0.996
1:59607876:T:C	L326P	0.996
1:59340017:T:G	C87W	0.995
1:59346280:A:T	D116V	0.995
1:59456968:T:C	C188R	0.995
1:59456982:T:G	C192W	0.995
1:59456985:G:C	K193N	0.995
1:59456985:G:T	K193N	0.995
1:59554218:T:G	C298W	0.995
1:59607840:G:A	G314E	0.995
1:59660285:G:C	A430P	0.995
1:59321726:G:C	W59C	0.994
1:59321726:G:T	W59C	0.994
1:59346286:G:C	R118P	0.994
1:59512401:T:A	V254D	0.994
1:59512418:G:C	D260H	0.994

dbSNP variants (sampled 300 via entrez): RS1000004708 (1:59706320 G>A), RS1000010106 (1:59488026 T>G), RS1000018536 (1:59339397 A>T), RS1000025677 (1:59640146 C>A), RS1000032875 (1:59630055 A>C), RS1000038847 (1:59554569 T>A), RS1000039562 (1:59668836 A>C,G), RS1000041871 (1:59450308 T>G), RS1000051155 (1:59371696 A>G), RS1000058475 (1:59587024 G>A), RS1000060352 (1:59497947 A>G), RS1000073044 (1:59450061 G>T), RS1000080700 (1:59598466 T>G), RS1000090049 (1:59756740 C>A,T), RS1000091816 (1:59673904 G>A)

Disease associations

OMIM: gene MIM:611370 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

18 associations (top):

Study	Trait	p-value
GCST000514_5	Response to antipsychotic therapy (extrapyramidal side effects)	7.000000e-06
GCST001059_19	Neutrophil count	3.000000e-06
GCST001762_168	Obesity-related traits	5.000000e-06
GCST001762_741	Obesity-related traits	2.000000e-06
GCST002700_4	Cervical artery dissection	2.000000e-07
GCST003158_1	Subjective response to lithium treatment	6.000000e-07
GCST004278_51	Pulse pressure	2.000000e-24
GCST004651_5	Aortic root size	3.000000e-09
GCST004775_2	Pulse pressure	5.000000e-07
GCST004775_36	Pulse pressure	3.000000e-20
GCST007102_1	Seasonality and depression	3.000000e-06
GCST009615_1	Triglyceride levels x loop diuretics use interaction	6.000000e-08
GCST009615_2	Triglyceride levels x loop diuretics use interaction	4.000000e-06
GCST010796_1312	Electrocardiogram morphology (amplitude at temporal datapoints)	1.000000e-08
GCST010796_1313	Electrocardiogram morphology (amplitude at temporal datapoints)	2.000000e-09
GCST90002393_32	Monocyte count	6.000000e-10
GCST90002394_138	Monocyte percentage of white cells	5.000000e-15
GCST90011899_102	Aspartate aminotransferase levels	2.000000e-10

EFO canonical traits (9, from GWAS)

EFO ID	Trait name
EFO:0004833	neutrophil count
EFO:0004501	HOMA-IR
EFO:0005763	pulse pressure measurement
EFO:0006876	seasonality measurement
EFO:0004530	triglyceride measurement
EFO:0004327	electrocardiography
EFO:0005091	monocyte count
EFO:0007989	monocyte percentage of leukocytes
EFO:0004736	aspartate aminotransferase measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

40 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	decreases expression, increases methylation	6
Aflatoxin B1	affects expression, decreases expression, increases methylation	5
Arsenic	affects methylation, increases abundance, increases expression, affects cotreatment, decreases expression	3
bisphenol A	decreases methylation, increases expression, affects cotreatment	2
sodium arsenite	affects cotreatment, decreases expression, increases abundance, increases expression	2
bufotalin	decreases expression	1
methylmercuric chloride	decreases expression	1
methyleugenol	decreases expression	1
alpha phellandrene	increases expression	1
triphenyl phosphate	affects expression	1
sodium arsenate	increases abundance, increases expression	1
ethyl-p-hydroxybenzoate	decreases expression	1
3,4,5,3’,4’-pentachlorobiphenyl	decreases expression	1
benzo(e)pyrene	increases methylation	1
aflatoxin B2	increases methylation	1
di-n-butylphosphoric acid	affects expression	1
quinocetone	increases expression	1
bisphenol S	increases methylation	1
jinfukang	increases expression	1
Sunitinib	increases expression	1
Fulvestrant	affects cotreatment, decreases methylation	1
Acetaminophen	decreases expression	1
Air Pollutants	decreases expression	1
Atrazine	increases expression	1
Cadmium	increases expression, decreases reaction	1
Cisplatin	decreases expression	1
Methapyrilene	increases methylation	1
N-Nitrosopyrrolidine	decreases expression	1
Nickel	decreases expression	1
Selenium	decreases reaction, increases expression	1

Cellosaurus cell lines

2 cell lines: 2 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_SN55	HAP1 FGGY (-) 1	Cancer cell line	Male
CVCL_XN76	HAP1 FGGY (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.